FridayJan 09, 2026 10:00 am

New ‘Nanozigzag’ Biomaterial Shows Potential in Revolutionizing Cancer Immunotherapy

Immunotherapy has emerged as a more gentle way to treat cancer over the past few years. However, it is very expensive and results are usually inconsistent among patients, especially those suffering from solid tumors. Researchers in Hong Kong have come up with a biomaterial containing silica that can help to address the current shortcomings of immunotherapy and dramatically improve efficacy rates.  Prof. Yung Kin-lam, who led the team of researchers, explains that the nanomaterial they developed is biocompatible, non-toxic, natural and comes in the shape of a nanomatrix. This biomaterial accelerates the maturation of dendritic cells (DCs) outside the body of the patient and these are infused into the patient to wake up the body’s ability…

Continue Reading

ThursdayJan 08, 2026 10:00 am

Analysis Finds 40 Million Individuals Seek Health Care Advice from ChatGPT

At least 40 million individuals from around the world use ChatGPT each day seeking information on health care-related topics, an analysis conducted by AI tool Knit. The report underscores how people use the technology and the need for oversight so that millions don’t get wrong information on such an important matter as their health.  The report shows that patients view the AI chatbot ChatGPT like an ally as they navigate health care-related issues they are facing.  The uses for which people seek out help from the chatbot include getting help interpreting medical bills, identifying any overcharges in those bills, how to appeal an insurance claim denial or even self-diagnosis in situations when a health care…

Continue Reading

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

Continue Reading

MondayJan 05, 2026 10:00 am

The WHO Highlights Successes, Challenges to Global Health

The World Health Organization (WHO), the agency of the United Nations responsible for overseeing matters related to global health, revealed that 2025 was marked by notable progress in ensuring populations around the world were supported to have good health. However, climate shocks, conflicts and funding cuts strained many health systems around the world and put a damper on the prospects for sustained improvements to health in the years to come.  Regarding disease control, the health body highlighted notable successes that were registered. For example, it pointed out a number of countries that hit historic milestones in the elimination of infectious diseases. Brazil stood out as…

Continue Reading

MondayDec 29, 2025 10:00 am

Experts’ Views on Screen Time and Lifestyle on Pediatric Brain Tumors

The young population faces an increasing health challenge posed by brain tumors affecting adolescents and children. While their occurrence isn’t as common as that of other cancers in this demographic group, brain cancers account for the biggest fraction of fatalities related to cancer in this group. Many questions have therefore emerged regarding whether modern screens and lifestyles play a role in the rise of brain cancer among younger people.  The general consensus within the scientific community is that there is no rigorous evidence suggesting that extensive time on screens or the use of mobile phones plays a causative role in the growing cases of brain tumors among adolescents…

Continue Reading

TuesdayDec 23, 2025 10:00 am

New Approach Could Increase Response Rates for Cancer Immunotherapy

Immunotherapy, an approach that seeks to stimulate the immune system to attack and destroy cancer cells, is a new field of research that has shown remarkable results in some patients. However, the overall fraction of patients who can benefit from immunotherapy is still very low, and researchers have been looking for ways to make this treatment modality work for a lot more patients.  Now, a team from Stanford University and MIT has developed a novel method through which the immune system can be primed to attack tumors in a way that could significantly improve response rates for more patients.  For their study, the team focused on glycans, sugar molecules that exist on…

Continue Reading

TuesdayDec 23, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline

OTLC’s Deciparticle(TM) platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current Preclinical PK data show that Sapu003, the intravenous Deciparticle(TM) formulation of Everolimus (Afinitor(R)), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering. Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new…

Continue Reading

MondayDec 22, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study

Soligenix reported that SGX302 was well tolerated by all patients in cohort 3, with no drug-related adverse events identified during the treatment period. An optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application. SGX302 utilizes visible light-activated synthetic hypericin, a first-in-class photodynamic therapy mechanism. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation…

Continue Reading

FridayDec 19, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing need for effective countermeasures. Ricin is a potent toxin capable of causing death within days of exposure because it stops protein synthesis inside cells, leading to organ failure. Soligenix has demonstrated meaningful preclinical efficacy for its ricin vaccine candidate. A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin…

Continue Reading

FridayDec 19, 2025 9:00 am

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration. On Wednesday, the exclusion of a provision extending the ACA tax credits triggered a revolt within the GOP ranks as some moderates in their ranks joined Democrats in signing a discharge petition that would compel the House to conduct a vote on extending the tax credits for 3 years. However, none of the Republicans who signed this petition eventually voted against the…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000